It was recently shown that copper chelators such as penicillamine, used to treat Wilson disease (copper-overload disorder), were able to slow growth of oncogenic BRAFV600E-driven tumors in mice, through inactivation of MEK1 (Brady et al., 2014). Here, MAP2K1 is linked to Wilson disease.